Is Faster Safer? Cluster Versus Short Conventional Subcutaneous Allergen Immunotherapy

Quiralte, Joaquín; Justicia, José L; Cardona, Victòria; Dávila, Ignacio; Moreno, Estefanía; Ruiz, Berta; Garcia, Mario

doi:10.2217/imt.13.133

Cited by 7 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,17 Though our study was not completely consistent with other studies, we indeed observed this result. Besides, our result was in accordance with Quiralte et al' study, 16 which also found that the incidence of adverse reactions with cluster schedules is lower than with conventional schedules. On the one hand, we thought it was related to the sample size.…”

Section: Discussionsupporting

confidence: 92%

“…This has the advantage of a reduced number of hospital visits, which reduces the time and expense required. Several studies have compared the efficacy and safety of cluster schedules versus conventional approaches, [15][16][17] but few reports on the efficacy and safety of the 2 SIT regimens in the initial stage have been published. In this randomized, open-label study, we compared the efficacy and safety of the build-up phase of the cluster schedule with that of the conventional schedule.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early Efficacy Analysis of Cluster and Conventional Immunotherapy in Patients With Allergic Rhinitis

Zhong

Luo

et al. 2019

Ear Nose Throat J

View full text Add to dashboard Cite

Background: Specific immunotherapy is an important immune-modifying treatment for patients with allergic rhinitis (AR). We compared the early efficacy and safety of cluster and conventional immunotherapies for patients with AR. Methods: One hundred forty-nine patients with persistent AR were enrolled in a randomized and open-label trial and were divided into the following 4 groups: 60 children treated conventionally, 33 children treated using the cluster schedule, 23 adults treated conventionally, and 33 adults treated using the cluster schedule. Patients in the cluster groups reached the maintenance dose within 6 weeks, while those receiving conventional therapy reached the maintenance dose within 14 weeks. Symptom scores and skin prick test scores (SPTs) were used to evaluate clinical efficacy and adverse reactions. Results: After buildup phase of treatment, symptom scores, and SPTs were significantly lower than those prior to treatment in each group ( P < .05). No significant differences were found in the efficacy of nasal symptoms scores among four groups ( P > .05).However, the efficacy of SPTs using conventional schedule was higher than cluster schedule in children groups (group A and B, 57.7 vs 30.2%, P = .001). Besides, the efficacy of SPTs in adults was higher than children when using the cluster treatment (group D and B, 53.0 vs 30.2%, P = .008). No severe adverse reaction occurred. Conclusions: Conventional and cluster immunotherapy schedules have similar efficacies, which do not vary with age; both schedules are safe and reliable. Also, SPT facilitate evaluation of clinical efficacy.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Early Efficacy Analysis of Cluster and Conventional Immunotherapy in Patients With Allergic Rhinitis

Zhong

Luo

et al. 2019

Ear Nose Throat J

View full text Add to dashboard Cite

show abstract

“…Fatal and nearfatal reactions in AIT tend to occur in the first 30 minutes, but not exclusively. [24][25][26] The inclusion of a rigid definition of time to onset might overlook severe reactions occurring not that acutely, as has been previously discussed, although all severe reactions in EASSI occurred 10 to 20 minutes after AIT administration.…”

Section: Discussionmentioning

confidence: 99%

Comparison of International Systemic Adverse Reactions Due to Allergen Immunotherapy

Vidal

Río

Gudé

et al. 2019

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

“…This study retrospectively assessed the safety and applicability of a cluster regimen in clinical routine for SCIT with HDM in a pediatric population of 21 patients with allergic asthma and/or allergic rhinitis. In the vast majority, AEs were mild and localized with a red swelling of less than 5 cm in diameter at injection sites, which is considered as common during SCIT and clinically not relevant [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. Systemic AEs and major local AEs were usually mild and occurred in 3 patients (14.3%) each.…”

Section: Discussionmentioning

confidence: 99%

“…risk of adverse events (AEs) than conventional updosing regimens [2][3][4][5]. Cluster and even rush regimens have been introduced into clinical routine for hymenoptera venom SCIT [6], but are less commonly used for aeroallergens such as house dust mites (HDM) [2] despite a safety profile comparable to conventional SCIT [3,7,8].…”

mentioning

confidence: 99%

Fast Updosing of Subcutaneous House Dust Mite Immunotherapy is Well Tolerated by Pediatric Patients

Köhli¹

2016

Int J Immunol Immunother

View full text Add to dashboard Cite

Data on the safety of a cluster regimen to start a subcutaneous immunotherapy (SCIT) with house dust mite (HDM) extract in pediatric patients are scarce. This study investigates the rate of adverse events (AEs) and the applicability of a cluster regimen for HDM SCIT in pediatric patients, and identifies possible risk factors for the development of AEs. A total of 147 injections with a depot extract (D. pteronyssinus / D. farinae, 50% each) were applied to 21 HDM-sensitized pediatric patients (age 5-18 years) with allergic asthma and/or allergic rhinitis within 2 weeks. All patients completed the cluster regimen with the full cummulative dose. Systemic adverse events (AEs) were mild to moderate (rhinitis, nausea or mild asthma), and occurred after 5 injections (3.4%) in three different patients (14.3%). Local AEs occurred in 14 patients (66.7%); 11 patients had minor local AEs and only 3 patients had major local AEs of a diameter ≥ 5 cm. All AEs developed within 60 minutes after the last injection. Patients with local AEs had higher total IgE serum levels than patients without AEs (p = 0.02). In conclusion, the cluster regimen for induction of HDM SCIT is a safe and well tolerated procedure in children.

show abstract

Is Faster Safer? Cluster Versus Short Conventional Subcutaneous Allergen Immunotherapy

Abstract: The safety profile of the cluster regimen supports the use of accelerated SCIT schedules with IR-standardized allergen extracts compared with short conventional schedules, particularly if similar extracts and application methods are used.

Cited by 7 publications

References 31 publications

Early Efficacy Analysis of Cluster and Conventional Immunotherapy in Patients With Allergic Rhinitis

Early Efficacy Analysis of Cluster and Conventional Immunotherapy in Patients With Allergic Rhinitis

Comparison of International Systemic Adverse Reactions Due to Allergen Immunotherapy

Fast Updosing of Subcutaneous House Dust Mite Immunotherapy is Well Tolerated by Pediatric Patients

Contact Info

Product

Resources

About